Remdesivir, an FDA-approved COVID-19 treatment, may carry a risk of bradycardic events — or a slowed heart rate — among hospitalized patients who had bradycardia, according to a study published Feb. 14 in JAMA.
Read the full post on Becker's Hospital Review - Healthcare News
